Table 2 Most commonly used adjuvants in therapeutic cancer trials
From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
Number of studies including most commonly used adjuvants/immunostimulants | ||||
|---|---|---|---|---|
Adjuvant | Phase 2 | Phase 2/3 | Phase 3 | Total |
GM-CSF | 92 | 1 | 16 | 109 |
Montanide | 60 | 1 | 5 | 66 |
IL-2 | 53 | 3 | 56 | |
KLH | 16 | 8 | 24 | |
TRICOM | 10 | 3 | 13 | |
QS21 | 5 | 1 | 6 | |
Poly-ICLC | 8 | 0 | 0 | 8 |